Personal information

No personal information available

Biography

Haiwen Huang, M.D., Ph.D.
Professor of Clinical Medicine
Division of Hematology
the First Afilliated Hospital of Soochow University

Dr. Huang Graduated from the Clinical Medicine Department of Suzhou Medical College in 1996, and obtained a master's degree in Hematology from Suzhou University in 2003 and a doctorate in 2009. From 2005 to 2006, he was awarded the Cheng Yu Tung Scholarship to study at the University of Hong Kong. He studied clinical hematology and lymphoma pathology at Montpellier University Hospital in France during two periods, from 2006 to 2007 and from 2009 to 2010, and obtained qualifications as a specialist in hematology in France. In 2013, he conducted research at the University of California, Los Angeles. He is a high-level talent training target of Jiangsu Province's "Six Major Talent Peaks." He has participated in multiple projects funded by the National Natural Science Foundation of China and has received funding from the Jiangsu Provincial Natural Science Foundation, Jiangsu Provincial Natural Science Foundation. She has led multiple international and domestic multicenter clinical trials and has published over 40 papers as the first or corresponding author, and co-authored five books.

Professional Experience:
1996.8-2005.8 Resident No.2 Affiliated Hospital of Suzhou University
2005.9-2006.3 Research assistant Faculty of Medicine, HongKong University
2006.11-2007.10 Resident CHU de Montpellier, France
2007.11-2013.7 Attending, Associate professor No.2 Hospital of Suzhou University
2013.8-2013.12 Visiting scholar University of California in Los Angeles (UCLA)
2014.01- Professor No.1 Affiliated Hospital of Suzhou University

Recent Publication:
1.Exp Hematol Oncol. 2024 Jan 16;13(1):4. (corresponding author)
2. J Cancer Res Clin Oncol. 2023 Oct;149(13):11549-11560 ( Co-first author )
3. Nat Commun. 2023 Jun 20;14(1):3642 (Co-first author )
4. Ann Hematol. 2023 Mar;102(3):597-601. ( corresponding author )
5. Future Oncol. 2023 Jan;19(3):259-270. (Co-first author )
6. HEMATOLOGY. 2022, VOL. 27, NO. 1, 404–411 (corresponding author)
7. Front Oncol. 2022 Jan 4;11:770988.( Co-first author )
8. J Cancer Res Clin Oncol. 2021 Nov;147(11):3441-3445. (corresponding author)
9. Br J Haematol. 2021 Sep 16. doi: 10.1111(corresponding author)
10. Ann Hematol. 2019 May; 98(5):1259-1266. (Co-first author and corresponding author )
11. Biol Blood Marrow Transplant. 2017 Aug;23(8):1393-139(corresponding author)
12. LEUKEMIA & LYMPHOMA, 2017 May 16:1-5(Co-first author and corresponding author )
13. Int J Clin Exp Med 2017;10(4):7261-7265(corresponding author )
14. Haematologica, 2016; 101(s1): 686(Co-first author and corresponding author )

Activities

Works (2)

Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label study

American Journal of Hematology
2023-11 | Journal article
Contributors: Lijuan Deng; Zhiming Li; Huilai Zhang; Haiwen Huang; Jianda Hu; Lihong Liu; Ting Liu; Jie Jin; Zunmin Zhu; Wenyu Li et al.
Source: check_circle
Crossref

Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma

Journal of Cancer Research and Clinical Oncology
2021-11 | Journal article
Contributors: Qian Wang; Yibin Jiang; Qian Zhu; Yishan Duan; Xiaochen Chen; Ting Xu; Zhengming Jin; Caixia Li; Depei Wu; Haiwen Huang
Source: check_circle
Crossref